{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:06:23Z","timestamp":1782968783096,"version":"3.54.5"},"reference-count":118,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill &amp; Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-007155"],"award-info":[{"award-number":["INV-007155"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>Drug discovery for malaria has traditionally focused on orally available drugs that kill the abundant, parasitic blood stage. Recently, there has also been an interest in injectable medicines, in the form of monoclonal antibodies (mAbs) with long-lasting plasma half-lives or long-lasting depot formulations of small molecules. These could act as prophylactic drugs, targeting the sporozoites and other earlier parasitic stages in the liver, when the parasites are less numerous, or as another intervention strategy targeting the formation of infectious gametocytes. Generally speaking, the development of mAbs is less risky (costly) than small-molecule drugs, and they have an excellent safety profile with few or no off-target effects. Therefore, populations who are the most vulnerable to malaria, i.e., pregnant women and young children would have access to such new treatments much faster than is presently the case for new antimalarials. An analysis of mAbs that were successfully developed for oncology illustrates some of the feasibility aspects, and their potential as affordable drugs in low- and middle-income countries.<\/jats:p>","DOI":"10.3390\/tropicalmed7040058","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T22:23:23Z","timestamp":1649370203000},"page":"58","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Development of New Strategies for Malaria Chemoprophylaxis: From Monoclonal Antibodies to Long-Acting Injectable Drugs"],"prefix":"10.3390","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-9649","authenticated-orcid":false,"given":"Joerg J.","family":"Moehrle","sequence":"first","affiliation":[{"name":"Integrated Sciences, R&D, Medicines for Malaria Venture, Route de Pr\u00e9 Bois 20, CH-1215 Geneva 15, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bpg.2011.10.012","article-title":"Chemoprevention\u2014History and general principles","volume":"25","author":"Wu","year":"2011","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1016\/S2214-109X(18)30415-7","article-title":"Safe mass drug administration for neglected tropical diseases","volume":"6","author":"Dorlo","year":"2018","journal-title":"Lancet Glob. Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"20130434","DOI":"10.1098\/rstb.2013.0434","article-title":"The contribution of mass drug administration to global health: Past, present and future","volume":"369","author":"Webster","year":"2014","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"ref_4","unstructured":"World Health Organization (2022, March 18). World Malaria Report 2019. Available online: https:\/\/www.who.int\/publications-detail\/world-malaria-report-2019."},{"key":"ref_5","unstructured":"World Health Organisation (2022, March 18). In Proceedings of the Malaria Policy Advisory Committee Meeting, 10\u201312 April 2019. Available online: https:\/\/www.who.int\/malaria\/mpac\/mpac-april2019-session7-erg-mass-admnistration-drug-report.pdf."},{"key":"ref_6","unstructured":"World Health Organisation (2022, March 18). WHO Guidelines for Malaria 13 July 2021. Available online: https:\/\/app.magicapp.org\/#\/guideline\/LwRMXj\/section\/nYKmgj."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1038\/s41598-020-63283-2","article-title":"Role of a Concentration Gradient in Malaria Drug Resistance Evolution: A Combined within- and between-Hosts Modelling Approach","volume":"10","author":"Romphosri","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_8","unstructured":"Malaria Policy Advisory Committee Meeting, and World Health Organization (2022, March 18). The Role of Mass Drug Administration, Mass Screening and Treatment, and Focal Screening and Treatment for Malaria. Available online: http:\/\/www.who.int\/malaria\/mpac\/mpac-sept2015-erg-mda-report.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Hooft van Huijsduijnen, R., Kojima, S., Carter, D., Okabe, H., Sato, A., and Akahata, W. (2020). Reassessing therapeutic antibodies for neglected and tropical diseases. PLoS Negl. Trop. Dis., 14.","DOI":"10.1371\/journal.pntd.0007860"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12936-018-2549-1","article-title":"Injectable anti-malarials revisited: Discovery and development of new agents to protect against malaria","volume":"17","author":"MacIntyre","year":"2018","journal-title":"Malar. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"17050","DOI":"10.1038\/nrdp.2017.50","article-title":"Malaria","volume":"3","author":"Phillips","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3389\/fmicb.2016.01617","article-title":"Immune Escape Strategies of Malaria Parasites","volume":"7","author":"Gomes","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Padilla-Rodr\u00edguez, J.C., Olivera, M.J., and Guevara-Garc\u00eda, B.D. (2020). Parasite density in severe malaria in Colombia. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0235119"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1473-3099(07)70021-X","article-title":"Epidemiology and burden of malaria in pregnancy","volume":"7","author":"Desai","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S1473-3099(18)30066-5","article-title":"Burden, pathology, and costs of malaria in pregnancy: New developments for an old problem","volume":"18","author":"Rogerson","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1258\/om.2012.110014","article-title":"Pregnancy and multiple sclerosis","volume":"5","author":"Airas","year":"2012","journal-title":"Obstet Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra1213566","article-title":"Pregnancy and infection","volume":"370","author":"Kourtis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.semperi.2019.03.018","article-title":"An overview of malaria in pregnancy","volume":"43","author":"Bauserman","year":"2019","journal-title":"Semin. Perinatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1128\/CMR.00025-08","article-title":"Acquired Immunity to Malaria","volume":"22","author":"Doolan","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Aponte, J.J., Menendez, C., Schellenberg, D., Kahigwa, E., Mshinda, H., Vountasou, P., Tanner, M., and Alonso, P.L. (2007). Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med., 4.","DOI":"10.1371\/journal.pmed.0040359"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/1475-2875-12-401","article-title":"Repeated mass distributions and continuous distribution of long-lasting insecticidal nets: Modelling sustainability of health benefits from mosquito nets, depending on case management","volume":"12","author":"Penny","year":"2013","journal-title":"Malar. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1475-2875-11-122","article-title":"Malaria resurgence: A systematic review and assessment of its causes","volume":"11","author":"Cohen","year":"2012","journal-title":"Malar. J."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Mogeni, P., Williams, T.N., Fegan, G., Nyundo, C., Bauni, E., Mwai, K., Omedo, I., Njuguna, P., Newton, C.R., and Osier, F. (2016). Age, Spatial, and Temporal Variations in Hospital Admissions with Malaria in Kilifi County, Kenya: A 25-Year Longitudinal Observational Study. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002047"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12936-015-0805-1","article-title":"Age-shifting in malaria incidence as a result of induced immunological deficit: A simulation study","volume":"14","author":"Smith","year":"2015","journal-title":"Malar. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1046\/j.1365-3156.2003.01161.x","article-title":"The changing epidemiology of malaria in Ifakara Town, southern Tanzania","volume":"9","author":"Schellenberg","year":"2004","journal-title":"Trop. Med. Int. Health"},{"key":"ref_26","unstructured":"World Health Organisation (2020, January 13\u201314). WHO Technical Consultation to Review the Role of Drugs in Malaria Prevention for People Living in Endemic Settings. Proceedings of the Malaria Policy Advisory Committee Meeting, Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/malaria\/mpac-documentation\/mpac-may2020-session5-chemoprevention-meeting-report_0b60e941-b400-492a-8d53-ce88b678f758.pdf?sfvrsn=ffe6493f_21&download=true."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ndiaye, J.L.A., Ndiaye, Y., Ba, M.S., Faye, B., Ndiaye, M., Seck, A., Tine, R., Thior, P.M., Atwal, S., and Beshir, K. (2019). Seasonal malaria chemoprevention combined with community case management of malaria in children under 10 years of age, over 5 months, in south-east Senegal: A cluster-randomised trial. PLoS Med., 16.","DOI":"10.1371\/journal.pmed.1002762"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ward, A., Guillot, A., Nepomnyashchiy, L.E., Graves, J.C., Maloney, K., Omoniwa, O.F., Emegbuonye, L., Opondo, C., Kerac, M., and Omoluabi, E. (2019). Seasonal malaria chemoprevention packaged with malnutrition prevention in northern Nigeria: A pragmatic trial (SMAMP study) with nested case-control. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210692"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa2026330","article-title":"Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention","volume":"385","author":"Chandramohan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1473-3099(19)30156-2","article-title":"Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin\u2013piperaquine for the control of malaria in pregnancy in Indonesia: A cluster-randomised, open-label, superiority trial","volume":"19","author":"Ahmed","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101160","DOI":"10.1016\/j.eclinm.2021.101160","article-title":"Intermittent screening and treatment with artemisinin-combination therapy versus intermittent preventive treatment with sulphadoxine-pyrimethamine for malaria in pregnancy: A systematic review and individual participant data meta-analysis of randomised clinical trials","volume":"41","author":"Gutman","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S1473-3099(15)00246-7","article-title":"In celebration of the Jesuit\u2019s powder: A history of malaria treatment","volume":"15","author":"Harrison","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00436-016-5353-2","article-title":"Risk of drug resistance in Plasmodium falciparum malaria therapy\u2014A systematic review and meta-analysis","volume":"116","author":"Zhou","year":"2017","journal-title":"Parasitol. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.pt.2008.05.004","article-title":"Fitness costs of resistance to antimalarial drugs","volume":"24","author":"Felger","year":"2008","journal-title":"Trends Parasitol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.1210875","article-title":"Exploiting Malaria Drug Resistance to Our Advantage","volume":"333","author":"Cammack","year":"2011","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Macintyre, F., Adoke, Y., Tiono, A.B., Duong, T.T., Mombo-Ngoma, G., and Bouyou-Akotet, M. (2017). A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria. BMC Med., 9.","DOI":"10.1186\/s12916-017-0940-3"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12936-021-03749-4","article-title":"A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria","volume":"20","author":"Adoke","year":"2021","journal-title":"Malar. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1016\/S2214-109X(18)30228-6","article-title":"Malaria in pregnancy: A call for a safe, efficient, and patient-centred approach to first-trimester treatment","volume":"6","author":"Rao","year":"2018","journal-title":"Lancet Glob. Health"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"ref_40","unstructured":"Manis, J.P. (2022, March 18). Overview of Therapeutic Monoclonal Antibodies. Available online: https:\/\/www.uptodate.com\/contents\/overview-of-therapeutic-monoclonal-antibodies\/print."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/19420862.2018.1556465","article-title":"Antibodies to watch in 2019","volume":"11","author":"Kaplon","year":"2019","journal-title":"mAbs"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1586\/eci.10.77","article-title":"Treatment of cancer during pregnancy with monoclonal antibodies: A real challenge","volume":"6","author":"Azim","year":"2010","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2217\/imt.13.64","article-title":"Are monoclonal antibodies a safe treatment for cancer during pregnancy?","volume":"5","author":"Sarno","year":"2013","journal-title":"Immunotherapy"},{"key":"ref_44","first-page":"209","article-title":"Pharmacokinetics of Monoclonal Antibodies Used for Inflammatory Bowel Diseases in Pregnant Women","volume":"4","author":"Stone","year":"2014","journal-title":"J. Clin. Toxicol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12936-016-1675-x","article-title":"New developments in anti-malarial target candidate and product profiles","volume":"16","author":"Burrows","year":"2017","journal-title":"Malar. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1475-2875-12-187","article-title":"Designing the next generation of medicines for malaria control and eradication","volume":"12","author":"Burrows","year":"2013","journal-title":"Malar. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/s12936-018-2598-5","article-title":"A discovery and development roadmap for new endectocidal transmission-blocking agents in malaria","volume":"17","author":"Burrows","year":"2018","journal-title":"Malar. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nrd4573","article-title":"Malaria medicines: A glass half full?","volume":"14","author":"Wells","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1038\/s41467-019-11239-0","article-title":"Antimalarial activity of primaquine operates via a two-step biochemical relay","volume":"10","author":"Camarda","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1475-2875-11-79","article-title":"Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine\/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso","volume":"11","author":"Diarra","year":"2012","journal-title":"Malar. J."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Goh, Y.S., Peng, K., Ni Chia, W., Siau, A., Chotivanich, K., Gruner, A.-C., Preiser, P., Mayxay, M., Pukrittayakamee, S., and Sriprawat, K. (2016). Neutralizing Antibodies against Plasmodium falciparum Associated with Successful Cure after Drug Therapy. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159347"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Koffi, D., Varela, M.-L., Loucoubar, C., Beourou, S., Vigan-Womas, I., Tour\u00e9, A., Djaman, J.A., Tour\u00e9, A.O., and Perraut, R. (2017). Longitudinal analysis of antibody responses in symptomatic malaria cases do not mirror parasite transmission in peri-urban area of Cote d\u2019Ivoire between 2010 and 2013. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0172899"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1146\/annurev.genom.9.081307.164258","article-title":"African Genetic Diversity: Implications for Human Demographic History, Modern Human Origins, and Complex Disease Mapping","volume":"9","author":"Campbell","year":"2008","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1038\/nrdp.2017.79","article-title":"Snakebite envenoming","volume":"3","author":"Calvete","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Laustsen, A.H., and Dorrestijn, N. (2018). Integrating Engineering, Manufacturing, and Regulatory Considerations in the Development of Novel Antivenoms. Toxins, 10.","DOI":"10.3390\/toxins10080309"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.2174\/1381612822666160623073438","article-title":"From Fangs to Pharmacology: The Future of Snakebite Envenoming Therapy","volume":"22","author":"Laustsen","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.nbt.2011.03.018","article-title":"Antibodies in infectious diseases: Polyclonals, monoclonals and niche biotechnology","volume":"28","author":"Berry","year":"2011","journal-title":"New Biotechnol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.vaccine.2013.01.025","article-title":"Monoclonal antibodies for prophylactic and therapeutic use against viral infections","volume":"31","author":"Both","year":"2013","journal-title":"Vaccine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa2034031","article-title":"A Monoclonal Antibody for Malaria Prevention","volume":"385","author":"Gaudinski","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00063030-200923020-00003","article-title":"Strategies to Extend Plasma Half-Lives of Recombinant Antibodies","volume":"23","author":"Kontermann","year":"2009","journal-title":"BioDrugs"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","article-title":"Strategies for extended serum half-life of protein therapeutics","volume":"22","author":"Kontermann","year":"2011","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amsu.2014.09.001","article-title":"The history of monoclonal antibody development\u2014Progress, remaining challenges and future innovations","volume":"3","author":"Liu","year":"2014","journal-title":"Ann. Med. Surg."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s11095-015-1703-5","article-title":"Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model","volume":"32","author":"Zhao","year":"2015","journal-title":"Pharm. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1208\/s12248-013-9477-3","article-title":"Factors Influencing Magnitude and Duration of Target Inhibition Following Antibody Therapy: Implications in Drug Discovery and Development","volume":"15","author":"Chimalakonda","year":"2013","journal-title":"AAPS J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"576","DOI":"10.4161\/mabs.2.5.12833","article-title":"Properties of a general PK\/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets","volume":"2","author":"Davda","year":"2010","journal-title":"mAbs"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0166-6851(89)90071-6","article-title":"Enhancement or inhibition of Plasmodium falciparum erythrocyte reinvasion in vitro by antibodies to an asparagine rich protein","volume":"32","author":"Wahlgren","year":"1989","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4161\/mabs.1.5.9448","article-title":"Industrialization of mAb production technology: The bioprocessing industry at a crossroads","volume":"1","author":"Kelley","year":"2009","journal-title":"mAbs"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ces.2015.10.029","article-title":"Cost evaluation of antibody production processes in different operation modes","volume":"141","author":"Klutz","year":"2016","journal-title":"Chem. Eng. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejpb.2017.06.029","article-title":"High-concentration protein formulations: How high is high?","volume":"119","author":"Garidel","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_71","first-page":"2381468319896280","article-title":"The Costs of Implementing Vaccination With the RTS,S Malaria Vaccine in Five Sub-Saharan African Countries","volume":"4","author":"Sicuri","year":"2019","journal-title":"MDM Policy Pr."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1345\/aph.1AQ634","article-title":"Mosquirix (RTS,S): A novel vaccine for the prevention of Plasmodium falciparum malaria","volume":"46","author":"Wilby","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature21060","article-title":"Sterile protection against human malaria by chemoattenuated PfSPZ vaccine","volume":"542","author":"Surat","year":"2017","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"eaaz5629","DOI":"10.1126\/scitranslmed.aaz5629","article-title":"A double-blind, placebo-controlled phase 1\/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1","volume":"12","author":"Roestenberg","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/infdis\/jiy080","article-title":"Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies","volume":"217","author":"Zenklusen","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2958.2000.01730.x","article-title":"Shotgun DNA microarrays and stage-specific gene expression in Plasmodium falciparum malaria","volume":"35","author":"Hayward","year":"2000","journal-title":"Mol. Microbiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1172\/JCI70349","article-title":"Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection","volume":"124","author":"Foquet","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"E10438","DOI":"10.1073\/pnas.1715812114","article-title":"Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein","volume":"114","author":"Oyen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm.4513","article-title":"A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein","volume":"24","author":"Tan","year":"2018","journal-title":"Nat. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.immuni.2017.11.007","article-title":"Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies","volume":"47","author":"Triller","year":"2017","journal-title":"Immunity"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.4512","article-title":"A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite","volume":"24","author":"Kisalu","year":"2018","journal-title":"Nat. Med."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Zhang, M., Mandraju, R., Rai, U., Shiratsuchi, T., and Tsuji, M. (2017). Monoclonal Antibodies against Plasmodium falciparum Circumsporozoite Protein. Antibodies, 6.","DOI":"10.3390\/antib6030011"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1126\/science.aar5304","article-title":"Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope","volume":"360","author":"Imkeller","year":"2018","journal-title":"Science"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e01371-19","DOI":"10.1128\/AAC.01371-19","article-title":"A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers","volume":"20","author":"McCarthy","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e01837-18","DOI":"10.1128\/AAC.01837-18","article-title":"DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with Plasmodium falciparum","volume":"27","author":"Collins","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1038\/s41598-021-84622-x","article-title":"In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP)","volume":"11","author":"Livingstone","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.2174\/138161207781039805","article-title":"Malaria Stage-Specific Vaccine Candidates","volume":"13","author":"Kristoff","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Rodriguez-Morales, A.J. (2016). Pre-Erythrocytic Vaccine Candidates in Malaria. Current Topics in Malaria, IntechOpen.","DOI":"10.5772\/61868"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e00498-16","DOI":"10.1128\/IAI.00498-16","article-title":"The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines","volume":"85","author":"Espinosa","year":"2017","journal-title":"Infect. Immun."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Bergmann-Leitner, E.S., Mease, R.M., De La Vega, P., Savranskaya, T., Polhemus, M., Ockenhouse, C., and Angov, E. (2010). Immunization with Pre-Erythrocytic Antigen CelTOS from Plasmodium falciparum Elicits Cross-Species Protection against Heterologous Challenge with Plasmodium berghei. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012294"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/s41564-019-0462-1","article-title":"Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody","volume":"4","author":"Rawlinson","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Wang, L.T., Pereira, L.S., Kiyuka, P.K., Sch\u00f6n, A., Kisalu, N.K., Vistein, R., Dillon, M., Bonilla, B.G., Molina-Cruz, A., and Barillas-Mury, C. (2021). Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1010133"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/IAI.00977-07","article-title":"Preclinical Evaluation of the Safety and Immunogenicity of a Vaccine Consisting of Plasmodium falciparum Liver-Stage Antigen 1 with Adjuvant AS01B Administered Alone or Concurrently with the RTS,S\/AS01B Vaccine in Rhesus Primates","volume":"76","author":"Pichyangkul","year":"2008","journal-title":"Infect. Immun."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/s41467-017-01924-3","article-title":"Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25","volume":"8","author":"Scally","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2010.04.036","article-title":"The IC50 of anti-Pfs25 antibody in membrane-feeding assay varies among species","volume":"28","author":"Cheru","year":"2010","journal-title":"Vaccine"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1128\/IAI.01438-13","article-title":"Potent Malaria Transmission-Blocking Antibody Responses Elicited by Plasmodium falciparum Pfs25 Expressed in Escherichia coli after Successful Protein Refolding","volume":"82","author":"Kumar","year":"2014","journal-title":"Infect. Immun."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1128\/IAI.67.4.1688-1693.1999","article-title":"Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies","volume":"67","author":"Lobo","year":"1999","journal-title":"Infect. Immun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1038\/s41467-019-11980-6","article-title":"Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25","volume":"10","author":"McLeod","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41541-018-0065-5","article-title":"Antibody targeting of a specific region of Pfs47 blocks Plasmodium falciparum malaria transmission","volume":"3","author":"Canepa","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1084\/jem.20150032","article-title":"Basigin is a druggable target for host-oriented antimalarial interventions","volume":"212","author":"Zenonos","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_101","first-page":"1087","article-title":"Benzathine penicillin G in the treatment of syphilis","volume":"15","author":"Smith","year":"1956","journal-title":"Bull. World Health Organ."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40263-013-0083-9","article-title":"Long-Acting Injectable Formulations of New-Generation Antipsychotics: A Review from a Clinical Perspective","volume":"27","author":"Rauch","year":"2013","journal-title":"CNS Drugs"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejpb.2009.03.006","article-title":"Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment","volume":"72","author":"Baert","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biomaterials.2017.10.023","article-title":"Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles","volume":"151","author":"Zhou","year":"2018","journal-title":"Biomaterials"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1128\/AAC.03906-14","article-title":"Pharmacokinetics of Injectable, Long-Acting Nevirapine for HIV Prophylaxis in Breastfeeding Infants","volume":"59","author":"Cortez","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/jcpt.13182","article-title":"Pharmacokinetics, safety and tolerability of long-acting parenteral intramuscular injection formulations of doravirine","volume":"45","author":"Yee","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(20)30497-7","article-title":"Cabotegravir, a new option for PrEP","volume":"20","author":"Kirby","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/bcp.14219","article-title":"First-in-human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection","volume":"86","author":"Chughlay","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jphp.12984","article-title":"Lipophilicity and hydrophobicity considerations in bio-enabling oral formulations approaches\u2014A PEARRL review","volume":"71","author":"Ditzinger","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/mmy\/myv111","article-title":"Comparison between liposomal formulations of amphotericin B","volume":"54","author":"Gangneux","year":"2016","journal-title":"Med. Mycol."},{"key":"ref_111","unstructured":"Pfizer (2022, March 18). Product Monograph Penicillin G Benzathine. Available online: https:\/\/www.pfizer.ca\/sites\/g\/files\/g10037206\/f\/201710\/Bicillin_PM.pdf."},{"key":"ref_112","unstructured":"Holmes, K.K., Bertozzi, S., and Bloom, B.R. (2022, March 18). Malaria Elimination and Eradication, Major Infectious Diseases, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK525190\/."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12936-015-0675-6","article-title":"Rapid evolution of pyrethroid resistance prevalence in Anopheles gambiae populations from the cities of Douala and Yaound\u00e9 (Cameroon)","volume":"14","author":"Fossog","year":"2015","journal-title":"Malar. J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","article-title":"Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: An open-label, single-arm, multicentre, therapeutic efficacy study","volume":"21","author":"Uwimana","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","article-title":"Evidence of Artemisinin-Resistant Malaria in Africa","volume":"385","author":"Balikagala","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Abeyasinghe, R.R., Galappaththy, G.N.L., Gueye, C.S., Kahn, J.G., and Feachem, R.G.A. (2012). Malaria Control and Elimination in Sri Lanka: Documenting Progress and Success Factors in a Conflict Setting. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0043162"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1475-2875-13-59","article-title":"On the road to eliminate malaria in Sri Lanka: Lessons from history, challenges, gaps in knowledge and research needs","volume":"13","author":"Karunaweera","year":"2014","journal-title":"Malar. J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.7150\/ijbs.59149","article-title":"Development and application of therapeutic antibodies against COVID-19","volume":"17","author":"Ning","year":"2021","journal-title":"Int. J. Biol. Sci."}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/7\/4\/58\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:49:46Z","timestamp":1760136586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/7\/4\/58"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":118,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["tropicalmed7040058"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed7040058","relation":{},"ISSN":["2414-6366"],"issn-type":[{"value":"2414-6366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]}}}